Brought to you by 
GlaxoSmithKline licenses NeuroSearch depression compounds
20 Dec 2002
Executive Summary
GlaxoSmithKline and NeuroSearch (nervous system therapeutics) have entered an agreement to discover and develop drugs for depression and other mood disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GlaxoSmithKline licenses NeuroSearch depression compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice